Recherche
-
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.
(Blood Advances. vol. 5, n° 5, pp. 1442-1451, 2021-03-09)Article de revue -
JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes.
(Blood Cancer Journal. vol. 12, n° 4, pp. 56, 2022-04-08)Article de revueLibre accès -
Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group
(Blood. vol. 140, n° Supplement 1, pp. 9668-9669, 2022-11-15)Article de revue -
CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM.
(American Journal of Hematology, 2024-02-25)Article de revueLibre accès